Lineage LINE 深 沪
已收盘 12-19 16:00:00 美东时间
34.13
-0.180
-0.52%
华盛通- 最 高34.58
- 今 开34.15
- 成交量 507.20万股
- 最 低 33.67
- 昨 收 34.31
- 总市值 78.16亿
- 52周最高 60.7175
- 市盈率 静 --
- 换手率 2.21%
- 52周最低 32.455
- 委 比 -90.82%
- 总股本 2.29亿
- 历史最高 87.36
- 量 比 3.12
- 振 幅 2.65%
- 历史最低 32.455
- 每 手 1
- 风险率 8.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
12-19 10:15
Lineage declares $0.5275 dividend
Lineage (LINE) declares $0.5275/share quarterly dividend, in line with previous. Forward yield 6.15% Payable Jan. 21; for shareholders of record Dec. 31; ex-div Dec. 31. See LINE Dividend Scorecard, Y...
12-19 05:34
Baird Downgrades Lineage to Neutral, Lowers Price Target to $39
Baird analyst Nicholas Thillman downgrades Lineage (NASDAQ:LINE) from Outperform to Neutral and lowers the price target from $45 to $39.
12-18 19:13
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
12-18 10:54
美股异动 | 今年美国最大IPO来袭 Medline(MDLN.US)上市首日开盘大涨超20%
周三，美国医疗巨头Medline(MDLN.US)登陆美股市场，开盘报35美元，涨幅超过20%，IPO价格为29美元。截至发稿，该股涨幅扩大至超25%，报36...
12-17 23:59
Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy
Issued on behalf of Avant Technologies Inc. Equity Insider News Commentary VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- The cell therapy manufacturing sector reached a pivotal inflection poi...
12-17 00:53
Shares of REITs are trading higher after the Fed cut rates, which could drive a rotation into dividend-paying sectors.
Shares of REITs are trading higher after the Fed cut rates, which could drive a...
12-11 04:47
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
12-05 08:35
Citigroup Maintains Neutral on Lineage, Lowers Price Target to $38
Citigroup analyst Nick Joseph maintains Lineage (NASDAQ:LINE) with a Neutral and lowers the price target from $39 to $38.
12-05 02:30
